Influenza A virus H1N1 vaccine - EpiVax
Latest Information Update: 07 Jul 2016
At a glance
- Originator EpiVax
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza A virus H1N1 subtype
Most Recent Events
- 07 Jul 2016 Preclinical trials in Influenza-A virus H1N1 subtype (Prevention) in USA (Parenteral)